1-1 of 1
Keywords: Lutetium-177 PSMA
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Prediction of Lesion-Based Treatment Response after Two Cycles of Lu-177 Prostate Specific Membrane Antigen Treatment in Metastatic Castration-Resistant Prostate Cancer Using Machine Learning

Available to Purchase
Subject Area:
Further Areas
Ogün Bülbül, Demet Nak, Sibel Göksel
Journal: Urologia Internationalis
Urol Int (2025) 109 (2): 128–134.
https://doi.org/10.1159/000541628
Published Online: 30 September 2024
... tomography/computed tomography Lutetium-177 PSMA Prediction Prostate specific membrane antigen (PSMA) is expressed at high levels in 90% of prostate cancer metastases [ 1, 2 ]. Lutetium-177 (Lu-177) PSMA therapy is a radionuclide treatment that targets the PSMA molecule and prolongs overall...
View article titled, Prediction of Lesion-Based Treatment Response after Two Cycles of Lu-177 Prostate Specific Membrane Antigen Treatment in Metastatic Castration-Resistant Prostate Cancer Using Machine Learning
Open the PDF for Prediction of Lesion-Based Treatment Response after Two Cycles of Lu-177 Prostate Specific Membrane Antigen Treatment in Metastatic Castration-Resistant Prostate Cancer Using Machine Learning in another window